Oropharyngeal candidiasis
Fungal infection of the oral and pharyngeal mucosa caused by Candida spp. More common in immunocompromised patients. Treated with topical antifungals; severe cases require systemic fluconazole.
ICD-10 B37.02 drugs
Also known as: Oral thrush, Oral candidiasis
Drugs used for this condition
- AFluconazoleFirst line · Antifungals, triazole derivativesFirst-line systemic therapy for moderate to severe oropharyngeal candidiasis. Dose 100–200 mg/day for 7–14 days. Mild cases can be managed topically with nystatin or clotrimazole. In HIV-infected patients, systemic fluconazole is preferred due to higher efficacy.
- AItraconazoleSecond line · Antifungal, triazoleTreats oropharyngeal candidiasis including fluconazole-resistant infections. AEMPS keeps fluconazole as first-line and reserves itraconazole for resistance or intolerance.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit